Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system

Anthony B. Nesburn; Ilham Bettahi; Xiuli Zhang; Xiaoming Zhu; Winston Chamberlain; Rasha E. Afifi; Steven L. Wechsler; Lbachir Benmohamed

doi:10.1016/S1542-0124(12)70164-7

Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system

Anthony B. Nesburn
, Ilham Bettahi
, Xiuli Zhang
, Xiaoming Zhu
, Winston Chamberlain
, Rasha E. Afifi
, Steven L. Wechsler
, Lbachir Benmohamed

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Abstract

Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although ocular mucosal immunity is highly beneficial for achieving protective immunity, the induction of ocular mucosal immunity against ocular infectious pathogens, particularly herpes simplex virus type 1 (HSV-1), which is the leading cause of infectious corneal blindness, remains difficult. Recent developments in cellular and molecular immunology of the ocular mucosal immune system (OMIS) may help in the design of more effective and optimal immunization strategies against ocular pathogens. In this review, we highlight ocular mucosal immunoprophylactic and immunotherapeutic vaccine strategies that have been evaluated to control the many pathogens that attack the surface of the eye. Next, we describe the current understandings of the OMIS and elucidate the structure and the function of the humoral and cellular immune system that protects the surface of the eye. Results from our recent experiments using topical ocular delivery of peptides-CpG and lipopeptide-based vaccines against HSV-1 infection are presented. The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed.

Original language	English (US)
Pages (from-to)	178-187
Number of pages	10
Journal	Ocular Surface
Volume	4
Issue number	4
DOIs	https://doi.org/10.1016/S1542-0124(12)70164-7
State	Published - Oct 2006
Externally published	Yes

Funding

From the 1Laboratory of Cellular and Molecular Immunology, Department of Ophthalmology, and 2Virology Research Laboratory, Department of Ophthalmology, and 3Center for Immunology, University of California Irvine, Irvine, California, USA This work was supported by National Eye Institute of the National Institute of Health grants EY14017 and EY14900 (LBM), EY015225 and EY016663 (ABN), EY12823, EY13191 and EY015100 (SLW), a Research to Prevent Blindness challenge grant (LBM) and the Discovery Eye Foundation.

Funders	Funder number
National Eye Institute of the National Institutes of Health	EY016663, EY12823, EY14017, EY015225, EY14900, EY015100
National Eye Institute and Casey Eye Institute	R01EY013191
Research to Prevent Blindness
Discovery Eye Foundation
University of California, Irvine

Keywords

Conjunctiva-associated lymphoid tissue (CALT)
Epitope
Eye-associated lymphoid tissue (EALT)
Herpes virus
Immune response
Lipopeptide
Mucosa-associated lymphoid tissue (MALT)
Mucosal immune system
Ocular mucosal immune system (OMIS)
Vaccine

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1016/S1542-0124(12)70164-7

Cite this

@article{62f4a4fc7e60496dbade3d7577dfc1db,

title = "Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system",

abstract = "Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although ocular mucosal immunity is highly beneficial for achieving protective immunity, the induction of ocular mucosal immunity against ocular infectious pathogens, particularly herpes simplex virus type 1 (HSV-1), which is the leading cause of infectious corneal blindness, remains difficult. Recent developments in cellular and molecular immunology of the ocular mucosal immune system (OMIS) may help in the design of more effective and optimal immunization strategies against ocular pathogens. In this review, we highlight ocular mucosal immunoprophylactic and immunotherapeutic vaccine strategies that have been evaluated to control the many pathogens that attack the surface of the eye. Next, we describe the current understandings of the OMIS and elucidate the structure and the function of the humoral and cellular immune system that protects the surface of the eye. Results from our recent experiments using topical ocular delivery of peptides-CpG and lipopeptide-based vaccines against HSV-1 infection are presented. The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed.",

keywords = "Conjunctiva-associated lymphoid tissue (CALT), Epitope, Eye-associated lymphoid tissue (EALT), Herpes virus, Immune response, Lipopeptide, Mucosa-associated lymphoid tissue (MALT), Mucosal immune system, Ocular mucosal immune system (OMIS), Vaccine",

author = "Nesburn, \{Anthony B.\} and Ilham Bettahi and Xiuli Zhang and Xiaoming Zhu and Winston Chamberlain and Afifi, \{Rasha E.\} and Wechsler, \{Steven L.\} and Lbachir Benmohamed",

note = "Funding Information: From the 1Laboratory of Cellular and Molecular Immunology, Department of Ophthalmology, and 2Virology Research Laboratory, Department of Ophthalmology, and 3Center for Immunology, University of California Irvine, Irvine, California, USA This work was supported by National Eye Institute of the National Institute of Health grants EY14017 and EY14900 (LBM), EY015225 and EY016663 (ABN), EY12823, EY13191 and EY015100 (SLW), a Research to Prevent Blindness challenge grant (LBM) and the Discovery Eye Foundation.",

year = "2006",

month = oct,

doi = "10.1016/S1542-0124(12)70164-7",

language = "English (US)",

volume = "4",

pages = "178--187",

journal = "Ocular Surface",

issn = "1542-0124",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system

AU - Nesburn, Anthony B.

AU - Bettahi, Ilham

AU - Zhang, Xiuli

AU - Zhu, Xiaoming

AU - Chamberlain, Winston

AU - Afifi, Rasha E.

AU - Wechsler, Steven L.

AU - Benmohamed, Lbachir

N1 - Funding Information: From the 1Laboratory of Cellular and Molecular Immunology, Department of Ophthalmology, and 2Virology Research Laboratory, Department of Ophthalmology, and 3Center for Immunology, University of California Irvine, Irvine, California, USA This work was supported by National Eye Institute of the National Institute of Health grants EY14017 and EY14900 (LBM), EY015225 and EY016663 (ABN), EY12823, EY13191 and EY015100 (SLW), a Research to Prevent Blindness challenge grant (LBM) and the Discovery Eye Foundation.

PY - 2006/10

Y1 - 2006/10

N2 - Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although ocular mucosal immunity is highly beneficial for achieving protective immunity, the induction of ocular mucosal immunity against ocular infectious pathogens, particularly herpes simplex virus type 1 (HSV-1), which is the leading cause of infectious corneal blindness, remains difficult. Recent developments in cellular and molecular immunology of the ocular mucosal immune system (OMIS) may help in the design of more effective and optimal immunization strategies against ocular pathogens. In this review, we highlight ocular mucosal immunoprophylactic and immunotherapeutic vaccine strategies that have been evaluated to control the many pathogens that attack the surface of the eye. Next, we describe the current understandings of the OMIS and elucidate the structure and the function of the humoral and cellular immune system that protects the surface of the eye. Results from our recent experiments using topical ocular delivery of peptides-CpG and lipopeptide-based vaccines against HSV-1 infection are presented. The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed.

AB - Mucosal vaccination is proving to be one of the greatest challenges in modern vaccine development. Although ocular mucosal immunity is highly beneficial for achieving protective immunity, the induction of ocular mucosal immunity against ocular infectious pathogens, particularly herpes simplex virus type 1 (HSV-1), which is the leading cause of infectious corneal blindness, remains difficult. Recent developments in cellular and molecular immunology of the ocular mucosal immune system (OMIS) may help in the design of more effective and optimal immunization strategies against ocular pathogens. In this review, we highlight ocular mucosal immunoprophylactic and immunotherapeutic vaccine strategies that have been evaluated to control the many pathogens that attack the surface of the eye. Next, we describe the current understandings of the OMIS and elucidate the structure and the function of the humoral and cellular immune system that protects the surface of the eye. Results from our recent experiments using topical ocular delivery of peptides-CpG and lipopeptide-based vaccines against HSV-1 infection are presented. The future challenges and issues related to the ocular mucosal delivery of molecularly defined sub-unit vaccines are discussed.

KW - Conjunctiva-associated lymphoid tissue (CALT)

KW - Epitope

KW - Eye-associated lymphoid tissue (EALT)

KW - Herpes virus

KW - Immune response

KW - Lipopeptide

KW - Mucosa-associated lymphoid tissue (MALT)

KW - Mucosal immune system

KW - Ocular mucosal immune system (OMIS)

KW - Vaccine

UR - https://www.scopus.com/pages/publications/34447293406

UR - https://www.scopus.com/pages/publications/34447293406#tab=citedBy

U2 - 10.1016/S1542-0124(12)70164-7

DO - 10.1016/S1542-0124(12)70164-7

M3 - Article

C2 - 17146573

AN - SCOPUS:34447293406

SN - 1542-0124

VL - 4

SP - 178

EP - 187

JO - Ocular Surface

JF - Ocular Surface

IS - 4

ER -

Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system

Abstract

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this